Patent Asset Index for Alzheimer’s and Parkinson’s patents

As of today effective drugs for Alzheimer’s and Parkinson’s diseases are missing. In fact, Pharma giant Pfizer recently announced that they’re ending their research in this field. Which from an innovation analytics point of view does not come as a complete surprise.

The Patent Asset Index™ trend of patents for nervous system disorder drugs reveals that the quality of Pfizer’s patents in this field has been dropping steadily since 2005. Their R&D expenditures simply did not pay off.

In contrast, the patent strength of Roche’s portfolio in the same field is rising steadily.

Related Content

Webinar Recording: Examining Apple’s Blockbuster Purchase of Intel’s Assets This webinar features a conversation on the news that Apple will purchase Intel assets for $1 billion. This news broke after it was reported that Inte...
10 Charts That Will Change Your Perspective Of Amazon’s Patent Growth This article originally appeared on Forbes.com, written by Louis Columbus Since 2010 Amazon has grown its patent portfolio from less than 1,000 active...
Autonomous Driving: how to judge strategic partnerships? Our competitors no longer just make cars. Companies like Google, Apple and even Facebook are what I think about at night. ―Akio Toyoda While...

By continuing to use the site, you agree to the use of cookies. Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close